This teaser solution originally appeared as part of a Friday File for the Irregulars on December 15. The ads are still running, this time under headlines like “Time to Bet the Farm”, so we’re taking another look, including my updated thoughts following the last quarterly report (I own this one), but most of the teaser […]
Articles
- Most Relevant
- Most Recent
Another month, another big pitch about a biotech stock with a great “P-Value Indicator” from Ernie Tremblay, all in an ad for his Biotech Insider Alert. Should we pay attention? Well, we can hardly avoid noticing it — we’re being battered about the head and neck with the constant email fusillade from Tremblay’s publisher and […]
Ray Blanco seems to love pitching a good “results coming soon” story for his FDA Trader ($1,495, no refunds) newsletter over at Agora, and this one is no different from dozens of others he has touted in the past… though the stock is one I haven’t seen him tease before. OK, fine, yes, I know […]
I suppose I should expect this by now — whenever Frank Curzio and the gang put out a teaser for Phase 1 Investor, which is the big-money newsletter from Stansberry & Associates ($5,000/year, though almost always “on sale” at $3,000 when they’re running promos), my inbox gushes like Spindletop. Didn’t matter if it was a […]
Lots to talk about today… we’ll start with a quick teaser solution, then move on to some big picture thoughts, updates on the changes in my portfolio (a couple small buys), and some other little updates and cogitations. The teaser comes from Mike Cintolo’s Cabot Growth Investor, which is just what it sounds like: a […]
This is a quickie, dear friends, because, well, it’s a teaser pitch we’ve covered before. But I thought it worthwhile to take another quick look — and not just because I actually own the stock (though I’m sure I do pay more attention to stocks I own than to others). See, this one’s an opportunity […]
This article originally ran on January 29, but must be circulating again in March because we’re getting questions from readers — so we re-share it with you today. In case you’re wondering, this “value” stock is now about 25% lower than it was when this article first hit our pages (and the ad first hit […]
We see “Amazon can’t beat this one” ads every now and again for retailers — that was part of Oxford Club’s push for Planet Fitness earlier this week, for example — but this one is generating quite a few questions… and I haven’t written about one of Hilary Kramer’s ads for a while, so it […]
This ad sounds very similar to some that we’ve looked at in the past, but readers always want to hear about these “top stock for the year” pitches so I thought I’d give it a look… after all, who doesn’t want an “almost easy double?” Mike Cintolo is using this spiel to sell his Cabot […]
No, this one’s not about you and your Uncle Bill. And it’s not about the little Gumshoes and their struggle with Algebra. It’s a headline from Frank Curzio, who earlier in the week sent out a hint-y email to at least a few folks that said, “How to capitalize on America’s most ‘stupid’ family.” It’s […]
Today’s tease comes in for the Money Map Report, in some articles where they hint around about the best way to double your money on the stock they think can be the “Next Whole Foods.” The pick is by Keith Fitz-Gerald, but We get a bit of an introduction from Steve Christ in a free […]
As we close in on the end of the first quarter, it’s time to release some more data — I just posted the 2019 teaser tracking spreadsheet for you, you can find it on the tracking page along with all our previous years and use it both to see what we’ve been covering so far […]
Today’s teaser happens to also concern a stock that I’ve been curious about, so I’m taking the opportunity to follow the hints down the rabbit hole and do a little chewing on whatever it is I find down there. The teaser ad comes in from Motley Fool Canada in an ad for their Stock Advisor […]
The ads that get the most attention tend to be either those that are most dramatically distributed, with seemingly every single email address getting multiple copies… or those that come with a big promise and a very high price. Today’s topic of interest is the latter, since we’re told that Stansberry Venture Value’s Dave Lashmet […]
I haven’t looked at Eifrig’s Income Intelligence in a long time, so it caught my eye when I saw the latest pitch for this Stansberry newsletter that is promising big gains in the very near future because a pick of theirs is likely to be added to the S&P 500. So let’s take a look […]
This was originally published as part of the Friday File on June 28, 2019. It has not been updated or revised (my position and disclosures remain the same). The ad under scrutiny today is for Jon Markman’s PowerElite service, which he says has a “retail price” of $228 but is “on sale” for $29/year at […]
Your Waistline and Your Lifeline: How Strong is that Link, Really?[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] Let me begin with a disclaimer: I am not skinny, but neither am I fat. This chapter […]
We’ve had a number of questions about this pitch for “The Next Chipotle” from Briton Ryle, so we’re re-posting this solution from December — the stock they’re teasing, ZOES, is still the same, though it reported a great first quarter in early June and the shares popped up on the news (and came back down […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] The word “placebo” is the first person singular, future tense, of the Latin verb “placere,” to please […]
I’ve gotten quite a few questions about the “Cash from Gold” pitch out of Agora Financial that hints at how easy it is to get “instant income.” So that’s today’s focus for you, dear readers. The big push at the end of the ad is “Yes, I want to collect at least $1,500 per month […]
We are right around the peak year for “number of people entering retirement” right now, and the stock market remains richly valued and a little nerve-wracking for the folks who are just beginning to think about living off of their investments… so I expect we’ll continue to see more pitches and promises about income investments […]
Which company? This is not Ozempic, Advil, or vitamin D… It’s an entirely new class of medicine that could earn you an absolute FORTUNE. Because not only can it make you smarter, make you stronger, and extend your life span by as much as 20 years… It’s also the most profitable drug in human history… […]
The world of psychedelics was briefly exciting for investors, mostly back around 2019-2020 or so, when everyone was looking for the next version of the cannabis bull market (remember that?)… and as potential for legalization of some drugs, like psilocybin (“magic mushrooms”), seemed to be in the wind, and old hallucinogenic or psychedelic compounds were […]
Finally, we take a short break from the A.I. mania to look at something else… this is the start of the pitch from Stansberry for Dr. David Eifrig’s Prosperity Investor(special deal is $2,500 for two years), with the ad introduced by Thomas Carroll, one of the analysts for that letter (John Engel is the other, […]
This article was originally published on August 4, 2022, but Ray Blanco has lately been pitching it as an urgent “last chance” idea because of their March 20, 2023 announcement, so we’re re-sharing this older article so folks can at least know what company he’s talking about (the preclinical results they announced at a conference […]
The first version of this story was published on March 4, 2021, and the ad we were covering was also a repeat of a pitch that started appearing about six months earlier. A very similar ad is online now (don’t know if it has been distributed, or if it’s just a lingering old copy), and […]
We’ll start out with the COVID-19 news. Yes, we’re all sick and tired of all COVID-related matters, but it doesn’t much lift our spirits to ignore COVID and pretend that it’s well and truly gone. We know better. It still lurks, and even though case rates and hospitalization rates are way down, people we know […]
We’ve got a strange confluence of events here, and it seems like the market is starting to draw dotted lines toward a more optimistic future… no buy or sell changes from me at the moment, just some musings about recent inflation optimism and China optimism, and how that tied in with some excitement over Berkshire’s […]
I’ve gotten a few questions in recent weeks about a new ad for Curzio Venture Opportunities ($249/month or $2,500/yr, no refunds), which is Frank Curzio’s “high end” upgrade newsletter, focusing on small cap stocks and stuff like junior miners, biotech and private placements. And this one’s a doozy, promoting the idea that a tiny company, […]
We’ll do a quickie for you today — a reader sent this question in, and was kind enough to even send the answer along with it, so we double-checked, fed his info through the Thinkolator, and I’ll share it with you. The pitch is from Chris Wood, dangling some bait to entice subscribers to his […]
My previous posting on Alzheimer’s focused on ways to avoid the most dire consequences of the disease in the absence of proven pharmaceutical interventions. The common assumption about disease management is that treatment begins when we develop symptoms. Then we go to the doctor, who most likely prescribes a course of treatment which probably includes […]
The last time Doc Gumshoe surveyed the Alzheimer’s landscape, the most prominent feature was the FDA’s approval – misguided, I thought – of Biogen’s Aduhelm (aducanumab) and the consequences this would have for everybody’s Medicare B premium. Sure enough, on November 12, 2021, the Centers for Medicare and Medicaid Services (CMS) confirmed the prediction that […]
Anyone interested in this one. Teekas last pre ipo went from $0.75 to $21.70 in a short time.
What started me down this path was a promotional piece for a new drug that was purported to suppress pain through a novel mechanism that prevented the nerve signal that conveyed to the brain a sensation that would usually be experienced as painful from actually being painful. In other words, while mincing an onion, you […]
Dr. David Eifrig has usually one of the more sober pitchmen at Stansberry (odd choice of words for a guy who owns a winery, I guess), and his Retirement Millionaire newsletter (usually sold at $49/yr, renews at $199) is probably his most conservative product — offering up “retirement living” lifestyle advice as well as what […]
Crypto stories are running hot and heavy once again, as Bitcoin and Ethereum have staked out dramatic new highs in recent months… and whenever that happens in a sector, we know the newsletter sales pitches will follow. I covered one of those in the Friday File last week from the Oxford Club folks, and today […]
Teaser from https://www.angelnexus.com/o/web/315108 ” Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on: The #1 Stock of This Generation Investors who get in on this tiny $5 stock… Stand to transform every $500 invested into $1.5 million.” Any ideas???
https://secure.stansberryinnovationsreport.com/?cid=MKT504365&eid=MKT518836&assetId=AST166792&page=1 I believe such an option will become available – any ideas what stock this would be though?
Hi Travis, I’d really appreciate your take on Maple Leaf Green World Inc. (MGW CA) It’s a TSA penny stock based in Calgary, Alberta. Momentum on it yesterday and today is exponentially higher than normal, and the price is up 25% over two days. I only notice it because it’s on my watchlist, since I’ve […]